CMAX Clinical Trial Facility For Phase I Study of Synthetic Antibiotic RECCE® 327. The Phase I clinical trial is a randomised, double blind, placebo-controlled single ascending dose study of 48healthy adult subjects. The study seeks to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of RECCE® 327 following intravenous administration. Completion Q4 2020. Patient screening Q1 2021
Yes, a brilliant post. Small point. Typo? Completion should be Q4 2021.
CMAX Clinical Trial Facility For Phase I Study of Synthetic...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $111.3M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 38.5¢ | 37.0¢ | $21.54K | 57.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3248 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49884 | 1 |
View Market Depth
| Last trade - 14.27pm 30/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |